Clinical TrialJun 3, 2026, 08:15 AM
TransCode Therapeutics Completes Phase 1a Trial; Reports Safety, Stabilization
AI Summary
TransCode Therapeutics, Inc. announced the successful completion of its Phase 1a dose escalation clinical trial for TTX-MC138, its lead therapeutic candidate. The trial met its primary endpoint of safety and tolerability, with no dose-limiting toxicities observed. The company reported durable disease stabilization in 64% of evaluable metastatic cancer patients and is now advancing TTX-MC138 into Phase 2a clinical development for patients with circulating tumor DNA (ctDNA) positive colorectal cancer.
Key Highlights
- Phase 1a clinical trial for TTX-MC138 successfully completed, meeting primary safety endpoint.
- No dose-limiting toxicities (DLTs) observed across all dose cohorts (0.8mg/kg to 4.8mg/kg).
- Durable disease stabilization achieved in 9 out of 14 (64%) evaluable metastatic cancer patients.
- Three patients remain on trial, with treatment durations up to 21 cycles.
- Recommended Phase 2a dose (RP2D) of 4.8mg/kg has been selected.
- Advancing TTX-MC138 into Phase 2a clinical development for ctDNA-positive colorectal cancer.
- One metastatic thyroid cancer patient showed a dramatic decrease in thyroglobulin levels and 12 months of stable disease.
Price Impact
More from RNAZ